APA (7th ed.) Citation

AM, T., C, V., D, S., HJ, L., H, H., MA, B., . . . D, X. (2026). Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3. The oncologist, 31(8), . https://doi.org/10.1093/oncolo/oyag254

Chicago Style (17th ed.) Citation

AM, Tsimberidou, et al. "Phase 2 Dose-expansion Trial of OBI-3424, a DNA-alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3." The Oncologist 31, no. 8 (2026). https://doi.org/10.1093/oncolo/oyag254.

MLA (9th ed.) Citation

AM, Tsimberidou, et al. "Phase 2 Dose-expansion Trial of OBI-3424, a DNA-alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3." The Oncologist, vol. 31, no. 8, 2026, https://doi.org/10.1093/oncolo/oyag254.